WOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society

Similar documents
Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

ARVs for prevention in at-risk populations: Microbicides

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

CAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina

International Partnership for Microbicides

Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017

Combination prevention: Public health and human rights imperatives

Where are we going after effectiveness studies?

UNAIDS 2018 THE YOUTH BULGE AND HIV

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:

Using anti-hiv drugs for prevention

Combination HIV Prevention

Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018

Antiretrovirals for HIV prevention:

Understanding the Impact of an HIV Intervention Package for Adolescents

Update on ARV based PrEP

Sierra Leone. HIV Epidemiology Report 2016

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

Sexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012

M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010

Translating the Science to End New HIV Infections in Kenya

The Big Picture: The current and evolving HIV prevention landscape

Young Mothers: From pregnancy to early motherhood in adolescents with HIV

The Open Label Trial Past and Present

Treatment as Prevention in India: What will it take?

Biomedical Prevention in HIV

HIV in Women. Why We Need Female- controlled Prevention. Heather Watts, MD March 21, 2017

Understanding the Results of VOICE

PrEP May Cause a Revolution in HIV Prevention: Time to Get Ready

Overview of ARV-based prevention trials

The Open Label Trial Past and Present

Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

IFMSA Policy Statement Ending AIDS by 2030

Biomedical Prevention Update Thomas C. Quinn, M.D.

Review of planned trials and key emerging issues for Thailand

Sex Work in Sub-Saharan Africa : Opportunities and Challenges

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

Pre-exposure Prophylaxis (PrEP)

Country Assessments to Strengthen Adolescent Component of National HIV Programme

HIV In South Africa: Turning the Tide of the Epidemic

REDUCING STRUCTURAL BARRIERS TO SCHOOLING: A MEANS TO REDUCE HIV RISK?

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

HIV Prevention. Recent Advances and Implications for the Caribbean

Can we treat our way out of the HIV epidemic?

EVIDENCE-BASED SOCIAL PROTECTION INTERVENTIONS FOR HIV PREVENTION

A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)

On the Fast-Track to end AIDS. HIV & AIDS in the Post 2015 Development Agenda

FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030

Aligning UNICEF s HIV Vision to the SDGs and UNAIDS Strategy. Dr. Chewe Luo Chief, HIV/AIDS Section UNICEF NYHQ 5 April 2016

Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013

Strategic use of antiretroviral drugs to prevent HIV transmission

PrEP in young African women: Rationale & lessons from HPTN 082

Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016

Why Are We Concerned About Adolescents Particularly Adolescent Girls and Young Women and HIV?

Pregnancies amongst adolescents and young women 16% of all births - 19% will have repeat pregnancies before age 20

Successful results of clinical trials

The Big Picture: The current and evolving HIV prevention landscape

ART and Prevention: What do we know?

Where We Have Been and Where We are Going. Ian McGowan MD PhD FRCP

ADOLESCENTS AND HIV:

Doing studies of ARV based

BUDGET AND RESOURCE ALLOCATION MATRIX

Translating Science to end HIV in Latin America and the Caribbean

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

Transmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa

UNAIDS 2013 AIDS by the numbers

HIV Prevention Strategies HIV Pre-exposure prophylaxis

Combination prevention for HIV How to evaluate whether it works? Marie Laga Institute of Tropical Medicine Antwerp, Belgium

Multiple choice questions: ANSWERS

HIV: A global perspective on epidemiology, diagnosis and prevention

Partnerships between UNAIDS and the Faith-Based Community

DREAMS. Heather Watts M.D. Senior Technical Advisor Office of the US Global AIDS Coordinator US Department of State

MTN 034/IPM 045: REACH Rings and PrEP in Young Women

Novel HIV Prevention Methods for Women

Strategic Plan Annual Results Briefing

Investing for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS

The Beginning of the End of AIDS Diane V. Havlir, MD

PEP and PrEP: AWAAC 2014

Ending the AIDS epidemic by 2030

From Ring to DREAM Mariëtte Malherbe IPM, Clinical Support Manager

STI and HIV Prevention and Care among Sex Workers

ViiV Healthcare s Position on Prevention in HIV

Sex differences in delayed antiretroviral therapy initiation among adolescents and young adults living with HIV in the Democratic Republic of Congo

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

Gender inequality and genderbased

Welcome and State of the Network. Cape Town, South Africa 27 th September 2016

PrEP in young African women: Rationale & lessons from HPTN 082 (and other studiesp

The outlook for hundreds of thousands adolescents is bleak.

What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women

NAMIBIA INVESTMENT CASE

WOMEN: MEETING THE CHALLENGES OF HIV/AIDS

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

Update on Antiretroviral-Based HIV Prevention

Children and AIDS Fourth Stocktaking Report 2009

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

Program to control HIV/AIDS

HP+/Project SOAR Oral PrEP Modeling. Webinar Series: Five Ways to Accelerate Progress Toward the Goals January 16, 2018

Transcription:

WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society

Objectives Review the current global burden of HIV among women Trends and progress to date Groups with heightened risk Examine key elements of the HIV response for women Ongoing gaps in response Areas for future research

Global HIV Burden among Women 35 million people are living with HIV 32 million adults and 3.2 million children 17.6 million women and girls HIV is the leading cause of death among women of reproductive age (15-49) globally Reference: UNAIDS 2014 Photo credit: CHANGE 2013

People Living with HIV by Region 58% of PLHIV in Africa are women or 15 million women and girls 71% of all PLHIV live in Africa or 25 million people Reference: WHO 2014

Trends, Progress & Gaps In 2013: 2.1 million new HIV infections Incident HIV infections are down 38% since 2001 Much slower declines among young women AIDS mortality has declined significantly 1.5 million deaths in 2013, down 35% since 2005 Declining steadily in women; not in 10-19 year olds 4000000 3000000 2000000 1000000 0 1980 1990 2000 2010 2020 New HIV Infections (global) AIDS-related deaths (global) Reference: UNAIDS 2014

Young Women & Girls In 2013, >60% of all new HIV infections globally in youth occurred among young women 380,000 adolescent girls were infected in 2013 AIDS is 2 nd leading cause death in adolescents Young women twice as likely to be infected then men in Africa Young women represent 25% of all new infections in the region Girls are 80% of incident HIV infections among adolescents 2013: 860 girls vs.170 boys infected per week in South Africa Reference: UNAIDS 2014

HIV among Young Women in Africa Young women are infected with HIV 5 to 7 years earlier on average Reference: UNAIDS 2014

Key Populations of Women Transgender women: Transgender women had a 48.8 times (95% CI 21 2 76 3) increased odds of being HIV-infected compared to adults overall. Female sex workers: Female sex workers had a 13.5 times (95% CI 10.0-18.1) increased odds of being HIVinfected compared to adult women. These groups often experience increased risk due to criminalization, stigma, discrimination and violence. References: Baral et al 2013; Kerrigan 2013; Baral 2012

HIV among Female Sex Workers Reference: Beyrer et al 2014

References: Boily et al 2009; Rao Gupta 2000 Biological, Behavioral and Structural Risks Biologically women twice as likely to become infected with HIV through unprotected heterosexual sex with an infected partner Heterosexual sex is main mode of transmission among women Young women and girls are particularly biologically vulnerable Lower social status of women and girls is reflected in a number of socio-structural determinants of their increased risk for HIV Inequitable gender norms Gender-based violence Discriminatory laws and policies Unequal opportunity structures Need for tailored, comprehensive combination HIV prevention for women (biomedical, behavioral and structural interventions)

PrEP, Adherence and Gender Effectiveness (%) 80 60 40 20 0-20 -40-60 VOICE (TFV gel) FemPrEP VOICE (TDF) iprex CAPRISA 004 VOICE (Truvada) PartnersPreP (FTC) PartnersPrep (TDF) TDF2 Pearson correlation = 0.86, p=0.003 0 20 40 60 80 100 Adherence by drug levels Reference: S. Abdool Karim, CAPRISA

Women and ART Women generally have greater access to HIV testing and ART than men through antenatal care (ANC): 67% of pregnant women in low and middle income countries received ART for PMTCT in 2013 Significant increase from 47% coverage in 2010 ANC screening often leaves out young women and girls, limiting HIV diagnosis and linkages to care FSW also found to have lower ART access Number of studies documented significantly lower levels of ART adherence among women compared to men FSW lower adherence than women overall Estimated 50% of FSW virally suppressed References: UNAIDS 2014; Mountain et al 2014

Expanding Women s Options Need for new ART-based prevention and treatment modalities more responsive to the lives of women Phase III RCTs of Vaginal Microbicide Rings RING Study (IPM 027) ASPIRE (MTN 020) Phase II RCTs of Long Acting Injectables (LAI) LAI for both PReP & ART Are LAI right for women?

Intimate Partner Violence & HIV Reference: WHO 2013

Integrating IPV into HIV Prevention The SHARE evaluation from Rakai, Uganda is first study to demonstrate a significant impact on both IPV and HIV incidence Individuals in the intervention reported less physical and sexual IPV and significant reductions in HIV incidence: airr 0.67; 95% CI 0.46 0.97 33% reduction in risk of HIV Reference: Wagman et al 2014

Cash Transfer Interventions Malawi: RCT with 1300 young women/girls (13-22); 3 arms: control, cash conditioned on school attendance & unconditional cash transfer up to $15/month 60% lower in HIV prevalence in cash transfer arms 76% lower HSV-2 & 35% lower pregnancy rate 25% less sexual partners including < older partners Benefits in both conditioned and unconditioned arms South Africa: 2 RCTs w/ HIV incidence outcomes in young women and girls will be key in impacting future programs: CAPRISA 007 & HPTN 078 Reference: Baird et al 2012

Reducing HIV among FSW Critical to address structural determinants of HIV risk through a comprehensive, community-led response: Elimination of sexual violence alone could avert 17-20% of HIV infections in Kenya and Canada over next decade Decriminalization of sex work could have the largest impact within both generalized and concentrated epidemics, averting 33-46% of HIV infections over the next decade Community empowerment responses (integrating biomedical, behavioral and structural interventions within human rights framework) associated with 32% reduction in odds of HIV References: Shannon et al 2014; Kerrigan et al 2014

Conclusions To sustainably reduce the HIV risk experienced by women we need both biomedical innovation and social change This will take a multisectoral and transdisciplinary approach integrating public health with the social sciences, human rights and economic development A more effective response to HIV will ultimately be grounded in the experiences and needs of women